Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered...
Substantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman,...
AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV therapies Led by nontuberculous mycobacteria (NTM) expert Dr. Kevin Winthrop,...
Advancing Phase 1 program in Chagas Disease; Phase 2 planning underway Clinical-stage M. abscessus program advancing through investigator-initiated trial (IIT) ...
AN2 awarded third year of funding from Gates Foundation
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that...
Cash, cash equivalents, and investments of $71.2 million at June 30,2025 and cash runway anticipated to fund operations into 2028
Preclinical studies in nonhuman primates naturally infected with T. cruzi have shown AN2-502998's curative potential in chronic Chagas disease ...